DRMA

Dermata Therapeutics Inc

Mar 18 • 04:00PM ET

1.19

-0.03 -2.46 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN LLY BIIB GILD AMGN ZTS BMRN ALNY IONS

Index	-	P/E	-	EPS (ttm)	-20.29	Insider Own	41.56%	Shs Outstand	2.84M	Perf Week	-9.16%
Market Cap	3.37M	Forward P/E	-	EPS next Y	-3.01	Insider Trans	0.08%	Shs Float	1.66M	Perf Month	-5.56%
Enterprise Value	-1.29M	PEG	-	EPS next Q	-1.54	Inst Own	0.95%	Short Float	6.78%	Perf Quarter	-52.02%
Income	-8.85M	P/S	-	EPS this Y	90.04%	Inst Trans	16.56%	Short Ratio	0.05	Perf Half Y	-79.85%
Sales	0.00M	P/B	0.25	EPS next Y	62.38%	ROA	-150.49%	Short Interest	0.11M	Perf YTD	-48.71%
Book/sh	4.69	P/C	0.72	EPS next 5Y	-	ROE	-203.36%	52W High	23.70 -94.98%	Perf Year	-90.08%
Cash/sh	1.65	P/FCF	-	EPS past 3/5Y	70.14% 43.22%	ROIC	-223.42%	52W Low	1.11 7.21%	Perf 3Y	-99.55%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.40% 10.64%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	90.53%	Oper. Margin	-	ATR (14)	0.16	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.56	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	41.23	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.56	EPS Q/Q	91.92%	SMA20	-6.08%	Beta	0.53	Target Price	10.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-30.91%	Rel Volume	0.02	Prev Close	1.22
Employees	8	LT Debt/Eq	0.00	Earnings	Nov 14 AMC	SMA200	-71.18%	Avg Volume	2.15M	Price	1.19
IPO	Aug 13, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-3.77% -	Trades		Volume	43,523	Change	-2.46%

Mar-10-26 08:30AM	Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing (ACCESSWIRE)
Mar-05-26 09:00AM	Dermata Opens a New Chapter with the Release of Tome Skincare (ACCESSWIRE)
Jan-20-26 08:05AM	Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office (ACCESSWIRE) -5.65%
Dec-29-25 04:05PM	Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) +22.58%
Dec-24-25 08:00AM	Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) +16.18%
08:00AM	Loading…
Dec-04-25 08:00AM	A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity (ACCESSWIRE) -16.28%
Nov-14-25 04:05PM	Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results (ACCESSWIRE) -7.49%
Oct-02-25 08:00AM	Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office (ACCESSWIRE)
Sep-17-25 01:00AM	Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025 (ACCESSWIRE) -5.50%
Sep-10-25 08:00AM	Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments (ACCESSWIRE) +5.97%
Aug-13-25 05:00PM	Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results (ACCESSWIRE) +5.48% -9.85%
Jul-08-25 08:00AM	Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis (ACCESSWIRE) -9.35%
May-14-25 09:00AM	Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results (ACCESSWIRE)
Apr-15-25 08:30AM	Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks (ACCESSWIRE)
Mar-27-25 08:15PM	Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) +5.19% -16.90%
08:00AM	Loading…
08:00AM	BREAKING: Dermata's XYNGARI Phase 3 Trial Topline Data Meets All Primary Endpoints (PR Newswire)
Mar-17-25 04:16PM	Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results (ACCESSWIRE)
Mar-04-25 08:03AM	Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI Phase 3 STAR-1 Clinical Trial for Acne (PR Newswire)
Feb-25-25 07:58AM	Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis (ACCESS Newswire) -6.67%
Jan-29-25 04:05PM	Dermata to Present on BioPub on January 31, 2025 (ACCESSWIRE)
Jan-23-25 04:15PM	Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) +12.26%
Jan-22-25 08:00AM	Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -16.54%
Jan-21-25 08:00AM	Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R) (ACCESS Newswire)
Dec-16-24 09:00AM	Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM) (ACCESSWIRE)
Dec-10-24 09:00AM	Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne (ACCESSWIRE)
Dec-03-24 09:00AM	Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne (ACCESS Newswire)
Nov-15-24 08:35AM	Life Sciences Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire) -5.79%
Nov-13-24 04:15PM	Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results (ACCESSWIRE)
Nov-12-24 08:35AM	Life Sciences Investor Forum Agenda Announced for November 14th (GlobeNewswire)
Nov-11-24 08:35AM	Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024 (GlobeNewswire)
04:15PM	Loading…
Oct-08-24 04:15PM	Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024 (ACCESSWIRE)
Sep-17-24 05:15PM	Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -11.21% +9.22%
Sep-16-24 09:00PM	Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) +46.84%
Sep-05-24 04:05PM	Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 (ACCESSWIRE) -5.30% +10.49%
Aug-07-24 11:53PM	DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q2 2024 (InvestorPlace) +12.45%
04:05PM	Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (ACCESSWIRE)
Jul-17-24 09:00AM	Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne (ACCESSWIRE)
May-17-24 08:30AM	Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -19.23%
May-15-24 10:54PM	DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +5.05%
04:05PM	Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (ACCESSWIRE)
May-13-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) +5.94%
Apr-03-24 07:00AM	Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now (GlobeNewswire)
Apr-02-24 07:00AM	Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now (GlobeNewswire)
Mar-27-24 04:05PM	Dermata to Present at the Emerging Growth Conference on April 3, 2024 (ACCESSWIRE)
Mar-21-24 10:53PM	DRMA Stock Earnings: Dermata Therapeutics Reported Results for Q4 2023 (InvestorPlace)
04:05PM	Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results (ACCESSWIRE)
Feb-07-24 07:00AM	Presenting on the Emerging Growth Conference 67 Day 2 on February 8 Register Now (GlobeNewswire)
Feb-06-24 07:00AM	Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now (GlobeNewswire)
Feb-01-24 09:00AM	Dermata to Present at the Emerging Growth Conference on February 7, 2024 (ACCESSWIRE) -6.67%
Jan-05-24 08:31AM	Why Is Dermata Therapeutics (DRMA) Stock Up 62% Today? (InvestorPlace) +11.49%
Jan-04-24 04:05PM	Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis (ACCESSWIRE)
Dec-20-23 04:05PM	Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne (ACCESSWIRE) -7.53%
Nov-17-23 09:06AM	Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug (Zacks)
Nov-16-23 01:30PM	Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) +6.72%
08:00AM	Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols (ACCESSWIRE)
Nov-09-23 04:05PM	Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results (ACCESSWIRE) +8.57% -7.72%
Oct-26-23 09:00AM	Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial (ACCESSWIRE)
Aug-31-23 09:00AM	Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference (ACCESSWIRE)
Aug-10-23 04:15PM	Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results (ACCESSWIRE)
Jun-27-23 09:00AM	Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne (ACCESSWIRE)
Jun-13-23 04:15PM	Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET (ACCESSWIRE) +6.55%
Jun-08-23 09:00AM	Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results (ACCESSWIRE)
May-26-23 04:00PM	Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -13.37% -6.17%
May-24-23 08:00AM	Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -9.72%
May-11-23 04:05PM	Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results (ACCESSWIRE) +8.43% +35.23%
May-10-23 11:46AM	Dermata Therapeutics awaits FDA go-ahead for lead candidate DMT310 to enter Phase 3 studies (News Direct)
Apr-21-23 12:02PM	Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate (Zacks) -8.04%
Apr-20-23 06:00AM	Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package (ACCESSWIRE) +11.72%
Mar-20-23 04:30PM	Dermata Therapeutics Announces Closing of $5.0 Million Public Offering (ACCESSWIRE) -10.67%
Mar-16-23 01:15PM	Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering (ACCESSWIRE) -21.63%
Feb-21-23 04:05PM	Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results (ACCESSWIRE)
Dec-05-22 08:30AM	Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea (ACCESSWIRE) -59.88%
Nov-10-22 05:20PM	Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results (ACCESSWIRE) +10.36%
Sep-06-22 09:00AM	Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference (ACCESSWIRE) +15.25%
Aug-24-22 04:05PM	Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase (ACCESSWIRE)
Aug-15-22 04:05PM	Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results (ACCESSWIRE)
Jun-13-22 09:00AM	Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea (ACCESSWIRE) -5.08%
May-23-22 09:00AM	Dermata to Present at the H.C. Wainwright Global Investment Conference (ACCESSWIRE) +7.14%
May-16-22 04:05PM	Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results (ACCESSWIRE) -9.71% -7.26%
Apr-25-22 04:50PM	Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -7.69%
Apr-21-22 09:00AM	Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE)
Mar-28-22 08:30AM	Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results (ACCESSWIRE)
Mar-24-22 08:30AM	Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference (ACCESSWIRE)
Feb-10-22 07:27AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +32.71%
Feb-07-22 08:58AM	Dermata Therapeutics Shares Plunge 20% Premarket: What Investors Need To Know (Benzinga) -34.68%
Jan-13-22 08:30AM	Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors (ACCESSWIRE)
Jan-05-22 08:30AM	Dermata to Present at the H.C. Wainwright BioConnect Conference (ACCESSWIRE) -6.43%
Nov-22-21 05:06AM	Companies Like Dermata Therapeutics (NASDAQ:DRMA) Are In A Position To Invest In Growth (Simply Wall St.) -26.89%
04:53AM	52 Biggest Movers From Friday (Benzinga)
Nov-19-21 02:17PM	Dermata's Aesthetic Improvement Candidate Fails To Impress - Read Why (Benzinga) -30.17%
08:30AM	Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions (ACCESSWIRE)
Nov-17-21 08:00AM	Dermata Announces First Patient Enrolled in its Phase 2 Trial of DMT310 for the Treatment of Moderate-to-Severe Rosacea (ACCESSWIRE)
Nov-15-21 04:01PM	Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-12-21 08:00AM	Dermata Announces Presentation Details for Its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting (ACCESSWIRE)
Nov-11-21 06:00AM	Dermata Announces Virtual Investor Event to Present DMT410 Phase 1b Proof of Concept Results in Aesthetic Skin Conditions (ACCESSWIRE)
Oct-19-21 07:00AM	18 Stocks Moving in Tuesday's Pre-Market Session (Benzinga)
06:53AM	Dermata Stock Jumps On Positive Psoriasis Candidate Data (Benzinga)

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bedoya-Toro Munera Maria E	SVP, Regulatory Affairs	Feb 17 '26	Buy	1.27	1,000	1,270	1,012	Mar 17 05:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DRMA

Dermata Therapeutics Inc

Upgrade your FINVIZ experience